X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (287) 287
Book / eBook (14) 14
Publication (11) 11
Book Review (3) 3
Book Chapter (2) 2
Magazine Article (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (117) 117
humans (113) 113
crown ethers (76) 76
male (69) 69
female (68) 68
crown ethers - therapeutic use (65) 65
quinazolines - therapeutic use (65) 65
lung neoplasms - drug therapy (63) 63
carcinoma, non-small-cell lung - drug therapy (56) 56
middle aged (51) 51
mutation (50) 50
gefitinib (48) 48
chemotherapy (46) 46
aged (44) 44
pharmacology & pharmacy (44) 44
antineoplastic agents - therapeutic use (43) 43
crown-ethers (40) 40
lung neoplasms - genetics (40) 40
icotinib (38) 38
analysis (37) 37
oncology (37) 37
chemistry, analytical (35) 35
adult (34) 34
carcinoma, non-small-cell lung - genetics (34) 34
erlotinib (34) 34
receptor, epidermal growth factor - genetics (34) 34
animals (33) 33
cancer (33) 33
lung neoplasms - pathology (32) 32
chemistry, multidisciplinary (31) 31
lung cancer, non-small cell (31) 31
lung cancer (30) 30
carcinoma, non-small-cell lung - pathology (29) 29
crown-ether (29) 29
chemistry (26) 26
treatment outcome (26) 26
crown ethers - adverse effects (25) 25
epidermal growth factor (25) 25
care and treatment (24) 24
crown ethers - administration & dosage (24) 24
quinazolines - adverse effects (24) 24
derivatives (23) 23
disease-free survival (23) 23
quinazolines - administration & dosage (23) 23
adenocarcinoma (22) 22
biochemistry & molecular biology (22) 22
chemistry, organic (22) 22
tyrosine kinase inhibitor (22) 22
crown ethers - chemistry (20) 20
receptor, epidermal growth factor - antagonists & inhibitors (20) 20
retrospective studies (20) 20
antineoplastic agents - pharmacology (19) 19
non-small cell lung cancer (19) 19
open-label (19) 19
research (19) 19
chemistry, medicinal (18) 18
mice (18) 18
aged, 80 and over (17) 17
cancer therapies (17) 17
crown ethers - pharmacology (17) 17
egfr (17) 17
erbb receptors - genetics (17) 17
genetic aspects (17) 17
neoplasm staging (17) 17
protein kinase inhibitors - therapeutic use (17) 17
trial (17) 17
adenocarcinoma - drug therapy (16) 16
cell line, tumor (16) 16
tyrosine (16) 16
1st-line treatment (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
crown ether (15) 15
health aspects (15) 15
stereoisomerism (15) 15
china (14) 14
organic chemistry (14) 14
respiratory system (14) 14
separation (14) 14
survival (14) 14
antineoplastic agents - adverse effects (13) 13
quinazolines - pharmacology (13) 13
apoptosis (12) 12
cell biology (12) 12
enantiomers (12) 12
lung neoplasms - mortality (12) 12
molecular recognition (12) 12
multicenter (12) 12
prognosis (12) 12
therapy (12) 12
tumors (12) 12
drugs (11) 11
ligands (11) 11
models, molecular (11) 11
mutations (11) 11
supramolecular chemistry (11) 11
usage (11) 11
adenocarcinoma - genetics (10) 10
adenocarcinoma - pathology (10) 10
cations (10) 10
chemistry, inorganic & nuclear (10) 10
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
UTL at Downsview - May be requested (5) 5
Dentistry (Harry R Abbott) - Stacks (3) 3
Gerstein Science - Stacks (3) 3
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Dentistry (Harry R Abbott) - Withdrawn (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 953 - 961
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, pp. e85245 - e85245
Journal Article
Lung Cancer, ISSN 0169-5002, 2010, Volume 73, Issue 2, pp. 195 - 202
Abstract Purpose The goal of this study was to assess the safety and tolerability of icotinib hydrochloride (BPI-2009H), a new selective epidermal growth... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Icotinib hydrochloride | Adverse events | Erlotinib | Tyrosine kinase inhibitor | Anti-tumor activity | Non-small-cell lung cancer | Pharmacokinetics | Gefitinib | Epidermal growth factor receptor | SURVIVAL | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | EXON-21 MUTATIONS | IMPACT | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | PROTEIN EXPRESSION | GENE COPY NUMBER | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Administration, Oral | Proto-Oncogene Proteins p21(ras) - genetics | Crown Ethers - blood | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Folliculitis - chemically induced | Quinazolines - blood | Crown Ethers - therapeutic use | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Antineoplastic Agents - blood | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Crown Ethers - adverse effects | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Medical colleges | Medical research | Care and treatment | Lung cancer, Non-small cell | Complications and side effects | Chemotherapy | Epidermal growth factor | Electrocardiogram | Phenols | Electrocardiography | Medicine, Experimental | Respiratory tract diseases | Cancer | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2014, Volume 84, Issue 3, pp. 295 - 300
Journal Article
The Lancet Respiratory Medicine, ISSN 2213-2600, 09/2017, Volume 5, Issue 9, pp. 707 - 716
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 03/2017, Volume 7, Issue 1, p. 45193
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2015, Volume 76, Issue 3, pp. 517 - 523
Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy... 
Icotinib | Medicine & Public Health | Non-small cell lung cancer | Oncology | Cancer Research | Brain metastases | Cerebrospinal fluid | Pharmacology/Toxicology | Whole-brain radiotherapy | GEFITINIB | METAANALYSIS | ADENOCARCINOMA | CHEMOTHERAPY | RADIATION-THERAPY | TYROSINE KINASE INHIBITORS | TRIAL | GROWTH-FACTOR RECEPTOR | ONCOLOGY | 2ND-LINE TREATMENT | PHARMACOLOGY & PHARMACY | ERLOTINIB | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Crown Ethers - cerebrospinal fluid | Crown Ethers - blood | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Chemoradiotherapy | Brain Neoplasms - metabolism | Brain Neoplasms - secondary | Crown Ethers - therapeutic use | Neoplasm Metastasis | Adult | Female | Brain Neoplasms - radiotherapy | Carcinoma, Non-Small-Cell Lung - pathology | Quinazolines - cerebrospinal fluid | Carcinoma, Non-Small-Cell Lung - metabolism | Brain Neoplasms - drug therapy | Quinazolines - blood | Disease-Free Survival | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Medical research | Brain | Medicine, Experimental | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Radiotherapy | Mass spectrometry | High performance liquid chromatography | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 6, pp. 9996 - 10006
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell... 
EGFR mutation | Icotinib | Gefitinib | Cost-effectiveness | Non-small cell lung cancer | non-small cell lung cancer | cost-effectiveness | MULTICENTER | ADENOCARCINOMA | gefitinib | OPEN-LABEL | PHASE-3 | NETWORK METAANALYSIS | MAINTENANCE THERAPY | CELL BIOLOGY | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | ERLOTINIB | icotinib | PLUS | Drug Costs | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Precision Medicine - economics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Models, Economic | Protein Kinase Inhibitors - adverse effects | Crown Ethers - therapeutic use | Pemetrexed - economics | Time Factors | China | Computer Simulation | Antineoplastic Combined Chemotherapy Protocols - economics | Crown Ethers - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Quality-Adjusted Life Years | Lung Neoplasms - enzymology | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Crown Ethers - economics | Molecular Targeted Therapy - economics | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolines - economics
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2014, Volume 86, Issue 2, pp. 207 - 212
Journal Article